Global Cord Blood Corporation (CO) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021
August 24, 2020 4:16 PM EDTHONG KONG, Aug. 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2021 ended June 30, 2020.
First Quarter of Fiscal 2021 Highlights
Revenues increased by 2.8% year-over-year ("YoY") to RMB280.9 million ($39.8 million). New subscribers and accumulated subscriber base were 17,233 and 849,933[1], respectively. Gross profit increased by 4.3% YoY to RMB237.5 million ($33.6 million). Gross margin improved to 84.5% from 83.3%... More